The objective of this program is to discuss the pathophysiology, disease burden, and management of heart failure (HF). The program will present data on HF prevalence and health outcomes, review the implications of type 2 diabetes as a common comorbidity, and provide guidance on diagnosing HF. It will conclude with a brief overview of current treatment options for HF.

This program follows two patients on their cardiovascular disease (CVD) journeys. Risk factors leading to the development and progression of atherosclerotic CVD and heart failure are discussed in the context of the patient experience over time. Strategies for primary and secondary prevention and optimization of guideline-directed medical therapy are also highlighted.

• Understand the disease burden and pathophysiology for acute ischemic stroke (AIS), and appreciate the underlying alterations in platelet physiology and phenotype in the context of AIS or high-risk transient ischemic attack (TIA). • Learn about the use of BRILINTA in patients with AIS and high-risk TIA and the differentiation of P2Y12 inhibitor use in this patient population • Appreciate the evidence and indications for BRILINTA across the spectrum of atherosclerotic and atherothrombotic disease by understanding the BRILINTA Pivotal Trials and the recently published THALES Trial

This program will review recent developments in the treatment of patients with chronic heart failure and discuss the important role of the primary care physician.

This webinar will educate primary care physicians on screening tools for assessment of axial spondyloarthritis, including referral strategies presented by the Assessment of SpondyloArthritis international Society (ASAS) and the Prevalence of Axial Spondyloarthritis (PROSpA) to help inform decisions on appropriate referrals to rheumatologists. This is the fifth chapter of a series of videos exploring early recognition of axSpA. Join us for a live webinar with Dr. Danve and Dr. Magrey on May 15.

During this presentation, Dr. Giles Whalen, a Surgical Oncologist, will review which patients are at highest risk for developing pancreatic cancer and how primary care providers can assist those patients. Dr. Whalen will also review which patients should be referred for genetic counseling or to a high risk screening program for pancreatic cancer surveillance. Dr. Tom King will then provide an overview of the IMMray® PanCan-d test, a blood test for the early detection of pancreatic ductal adenocarcinoma in individuals at high risk for developing familial or hereditary pancreatic cancer.

Pri-Med's new weekly CME/CE web series, Primary Care Pulse, features live conversations about timely topics and concerns facing primary care clinicians.

Pri-Med's new weekly CME/CE web series, Primary Care Pulse, features live conversations about timely topics and concerns facing primary care clinicians.

Pri-Med's new weekly CME/CE web series, Primary Care Pulse, features live conversations about timely topics and concerns facing primary care clinicians.

Pri-Med's new weekly CME/CE web series, Primary Care Pulse, features live conversations about timely topics and concerns facing primary care clinicians.

Pri-Med's new weekly CME/CE web series, Primary Care Pulse, features live conversations about timely topics and concerns facing primary care clinicians.

Pri-Med's new weekly CME/CE web series, Primary Care Pulse, features live conversations about timely topics and concerns facing primary care clinicians.